Gabbay currently serves as the chief scientific and medical officer at the American Diabetes Association, leading the organization’s efforts to drive discovery in diabetes research, care and prevention. He also serves as an associate professor of medicine at Harvard Medical School, having previously been CMO at Joslin Diabetes Center.
“The burdensome diabetes care regimens make people with this condition especially prone to nonadherence. For this reason, and many more, Dr. Gabbay is an exemplary fit for our advisory board,” Sweetch CEO Yoni Nevo said in a news release. “As we accelerate our growth and integration into more health and life science organizations, Dr. Gabbay’s deep understanding of such organizations and their patients will be invaluable.”
Tel Aviv-based Sweetch develops digital therapeutics and an engagement platform for chronic conditions. The company uses artificial intelligence and emotional intelligence in its clinically-validated digital therapeutics platform to move individuals to achieve their health goals through hyper-personalized recommendations at the right time, in the right tone and in real-world context.
“I am encouraged by many digital health providers incorporating AI into diabetes treatment, but platforms still lack contextual, just-in-time personalization, an absence that prevents them from fully delivering on their promises,” Gabbay said. “People with diabetes need better tools to help them navigate their diabetes every day to improve the quality of their lives. Solving these issues for people with diabetes will undoubtedly lead to better outcomes for people with chronic conditions worldwide.”
